Cargando…

Relative Bioavailability of a Dolutegravir Dispersible Tablet and the Effects of Low‐ and High‐Mineral‐Content Water on the Tablet in Healthy Adults

Dolutegravir (DTG) is approved in the United States to treat HIV‐1‐infected patients weighing ≥30 kg. A dispersible DTG tablet formulation was recently developed for pediatric patients. This study compares the pharmacokinetics (PK) of the dispersible tablet with that of a previously evaluated granul...

Descripción completa

Detalles Bibliográficos
Autores principales: Buchanan, Ann M., Holton, Michael, Conn, Ian, Davies, Mark, Choukour, Mike, Wynne, Brian R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697680/
https://www.ncbi.nlm.nih.gov/pubmed/28168828
http://dx.doi.org/10.1002/cpdd.332

Ejemplares similares